• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PM

    Philip Morris International Inc

    Subscribe to $PM
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

    IPO Year:

    Exchange: NYSE

    Website: pmi.com

    Peers

    $MO
    $BTI

    Recent Analyst Ratings for Philip Morris International Inc

    DatePrice TargetRatingAnalyst
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    11/16/2023$95.00Neutral
    Redburn Atlantic
    6/20/2023$109.00 → $117.00Neutral → Buy
    Citigroup
    4/14/2023$114.00Buy
    Stifel
    3/30/2023$109.00 → $116.00Neutral → Overweight
    JP Morgan
    See more ratings

    Philip Morris International Inc Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Philip Morris International Holds 2025 Virtual Annual Meeting of Shareholders

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) held its 2025 Annual Meeting of Shareholders today. André Calantzopoulos, Chairman of the Board, addressed shareholders and answered questions. Jacek Olczak, Chief Executive Officer, gave a business presentation, which included an overview of PMI's: excellent 2024 performance and impressive start to 2025; achievement of several key milestones in its smoke-free journey; positive results in the execution of its multicategory strategy; ability to deliver sustainable growth and returns in 2025 and beyond; steadfast commitment to shareholder returns. "Our smoke-free transformation continues to advance rapidly. We mark

      5/7/25 9:44:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International to Host Webcast of 2025 Virtual Annual Meeting of Shareholders

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast of its 2025 Annual Meeting of Shareholders on Wednesday, May 7, 2025, at 9:00 a.m. ET. The meeting will be in a virtual format and can be accessed at www.virtualshareholdermeeting.com/PM2025. Presentation slides, script and an archived recording of the webcast will be available at the same link. The recording will be available for one year from the date of the meeting. During the meeting, André Calantzopoulos, Chairman of the Board, and Jacek Olczak, Chief Executive Officer, will address shareholders and answer questions. Only shareholders of record with a valid 16-digit control number will be

      4/30/25 9:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International CEO Jacek Olczak Addresses Emerging Global Divide in Regulatory Approaches to Consumer Innovation

      Olczak issues call for pragmatic policies that accelerate advances in public health, noting that approximately 20% of smokers globally lack access to better alternatives to cigarettes Jacek Olczak, Chief Executive Officer of Philip Morris International Inc. (NYSE:PM), outlined the need for common-sense regulations in the consumer goods sector while addressing global leaders at Semafor's annual World Economy Summit in Washington, D.C., on April 25, 2025. Olczak emphasized the sector's potential for innovation-led growth despite the volatile economic environment. He stressed, however, that without appropriate regulation and policy frameworks to enable scientific evaluation and consumer acces

      4/28/25 8:15:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Reports First-Quarter 2025 Results and Raises 2025 Full-Year Adjusted Diluted EPS Forecast for Currency Only

      Reported Diluted EPS Grew 24.6% to $1.72 Adjusted Diluted EPS Grew 12.7% to $1.69; and by 17.3% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 first-quarter results.1 "We achieved exceptionally strong performance in the first quarter, with continued volume growth supporting an excellent top-line performance and very strong margin expansion," said Jacek Olczak, Chief Executive Officer. "Our smoke-free business goes from strength to strength, delivering organic growth of over 20% in net revenues and over 33% in gross profit." "We remain confident in our ability to deliver superior results, despite an uncertain and volatile glob

      4/23/25 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International to Host Webcast of 2025 First-Quarter Results

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast at www.pmi.com/2025Q1earnings on Wednesday, April 23, 2025, at 9:00 a.m. ET, to discuss its 2025 first-quarter financial results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast will be hosted by Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The webcast recording and the slides and script will be available a

      4/16/25 7:30:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • IQOS Collaborates with Italian Design Brand SELETTI: Introducing the 'Curious X: Sensorium Piazza' at Milan Design Week

      Challenging the status quo to realize something truly unexpected for a community of more than 32 million1 legal age users who have made the choice to move away from cigarettes In support of Philip Morris International's (NYSE:PM) mission to make cigarettes obsolete, and to celebrate its ever-growing community of more than 32 million users worldwide – IQOS is proud to announce its collaboration with iconic design brand SELETTI at Milan Design Week. "Curious X: Sensorium Piazza" – the new project that IQOS brings with the signature of SELETTI – is the name of the installation which will be available at Opificio 31, inside Tortona Rocks from April 7 to 13 2025. This bold reimagination of the

      4/7/25 6:01:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Releases Integrated Report Detailing Progress Towards Its Smoke-Free Vision

      The 2024 Integrated Report marks a decade of PMI's smoke-free journey and showcases the company's business transformation and key sustainability achievements, as evidenced by performance on its Sustainability Index 2022-24 Philip Morris International Inc. (NYSE:PM) today published its sixth annual Integrated Report, marking the company's 10th year of business transformation and sustainability disclosures. The document details PMI's continued progress in delivering long-term value to shareholders and other stakeholders while advancing its purpose of having its smoke-free alternatives make cigarettes obsolete as soon as possible. "Our 2024 Integrated Report celebrates a milestone year that

      4/3/25 4:30:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Court Approves CCAA Plans to Resolve Tobacco Product-Related Claims and Litigation in Canada

      Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding has approved a plan of compromise and arrangement for RBH (the Plan). The Plan, as approved, will resolve all tobacco product-related claims and litigation in Canada against RBH and its affiliates, including PMI. The court also approved substantially similar plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM). As previously disclosed, RBH's court-appointed mediator and monitor filed a pr

      3/7/25 8:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

      Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on April 10, 2025, to shareholders of record as of March 20, 2025. The ex-dividend date is March 20, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consist

      3/6/25 10:44:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Presents at 2025 CAGNY Conference; Reaffirms 2025 Full-Year Forecast

      Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Chief Executive Officer, Jacek Olczak, and Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 Consumer Analyst Group of New York (CAGNY) Conference. The event will be webcast live in listen-only mode, beginning at approximately 1:00 p.m. ET, at www.pmi.com/2025cagny and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). Presentation slides will also be available on the same site and the App. An archived copy of the webcast will be available until Friday, March 21, 2025. The presentation will cover: PMI's progress over the past decade to deliver a smoke-free future; t

      2/19/25 8:45:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    Philip Morris International Inc Leadership Updates

    Live Leadership Updates

    See more
    • Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

      Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

      9/17/24 9:11:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Names New External Affairs Leader

      Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

      3/26/24 5:48:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

      In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

      3/4/24 6:48:00 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kaival Brands Appoints Executive Chairman Barry Hopkins as Interim Chief Executive Officer and President

      GRANT-VALKARIA, Fla., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) ("Kaival Brands," the "Company," or "we") today announced that it has expanded the role of Barry M. Hopkins, Executive Chairman, to include the positions of Interim Chief Executive Officer & President. Former Chief Executive Officer & President, Eric Mosser, has been appointed Chief Executive Officer & President of Kaival Brands International, the Company's subsidiary which has an international licensing relationship with Philip Morris Products S.A., a wholly owned affiliate of Philip Morris International Inc. (NYSE:PM). Niraj Patel, Founder & Chief Science Officer of Kaival Brands

      12/28/23 8:30:00 AM ET
      $KAVL
      $PM
      Other Consumer Services
      Consumer Discretionary
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Appoints Finance Leader Victoria Harker to Its Board of Directors

      Philip Morris International Inc. (PMI) (NYSE:PM) announced today that on September 13, 2023, its Board of Directors appointed a new member, Ms. Victoria Harker, to serve on the Board of Directors, effective January 1, 2024. Victoria Harker is an experienced U.S. public-company Chief Financial Officer, having served in the role with three different companies, and she has been involved in significant corporate transformations in the consumer, industrial and utility sectors for over 25 years. She is a high-energy, action-oriented, strategic executive, who has worked at a significant scale, most recently as Executive Vice President and Chief Financial Officer of TEGNA Inc., a global media and

      9/18/23 7:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Announces Appointment of Two Former U.S. FDA Officials, Highlighting the Company's Continued Commitment to Smoke-Free Product Science and Regulation

      Dr. Badrul Chowdhury Appointed Chief Life Sciences Officer Dr. Matthew Holman Appointed Vice President, U.S. Scientific Engagement and Regulatory Strategy Philip Morris International Inc. (PMI) (NYSE:PM) announced today that it has appointed two former United States Food and Drug Administration (U.S. FDA) officials to key positions to accelerate its science-based transformation. Dr. Badrul Chowdhury is appointed PMI's Chief Life Sciences Officer, Smoke-Free Products, succeeding Jorge Insuasty, who will complete his move into the recently created position of President, Vectura Fertin Pharma. After a short transition period, Badrul will join PMI's Senior Management Team in January 2023,

      9/14/22 7:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Zayo Group Adds Telecommunications Leader Lisa Hook to Board of Directors

      Former Neustar President & CEO brings decades of leadership experience to Zayo board Zayo Group Holdings, Inc., a leading global communications infrastructure platform, today announced the appointment of Lisa Hook to its board of directors. Hook is a seasoned public company CEO, with extensive experience in cloud infrastructure, internet security, telecommunications, data analytics and digital marketing. "Lisa is a recognized leader with experience across multiple industries in the public and private sector," said Steve Smith, CEO of Zayo Group. "She will be an invaluable asset to our board as we continue to lead Zayo into its next phase of growth and service to our customers." Hook most

      5/25/22 10:00:00 AM ET
      $FIS
      $PM
      $RBA
      Business Services
      Consumer Discretionary
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Appoints Business Accelerator Dessi Temperley to its Board of Directors

      Philip Morris International Inc. (PMI) (NYSE:PM) today announced that on December 6, 2021, its Board of Directors appointed a new member, Ms. Dessislava ("Dessi") Temperley. Dessi Temperley is a former global public company CFO with more than 25 years of experience across a variety of sectors, working for several blue-chip multinationals. She has a proven track record of delivering strategic change with strong operational leadership resulting in superior financial results, most recently as Group CFO and Executive Board Member of Beiersdorf AG. Prior to this, she held several senior positions at Nestlé. She is also a non-executive member of the Board of Directors for Coca-Cola Europacific P

      12/10/21 6:30:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Lisa Hook to join Ritchie Bros.' Board of Directors

      VANCOUVER, BC, Oct. 18, 2021 /PRNewswire/ - Ritchie Bros. Auctioneers Incorporated (NYSE:RBA) (TSX:RBA) ("Ritchie Bros. and the "Company"), is pleased to announce the appointment of Lisa Hook to its Board of Directors, effective November 1, 2021 "We are pleased to welcome Lisa as our newest director. Her vast and diverse experience of transforming and scaling businesses with technology adds a valuable perspective to our Board" said Erik Olsson, Chairman of the Board for Ritchie Bros. Commenting on the appointment, Ann Fandozzi, CEO of Ritchie Bros., said: "I am excited by Lisa joining the board and helping Ritchie Bros achieve our strategic vision to be the trusted global marketplace for in

      10/18/21 5:59:00 AM ET
      $FIS
      $NSR
      $PING
      $PM
      Business Services
      Consumer Discretionary
      EDP Services
      Technology
    • Philip Morris International Organizes for Continued Innovation: Deepak Mishra Named President, Americas Region, Martin King to Retire After 30 Years of Service

      Jacek Olczak, Chief Executive Officer of Philip Morris International (PMI) (NYSE:PM), today announced a new structure for the Americas with the appointment of Deepak Mishra—formerly Chief Strategy Officer—as President, Americas Region, covering the United States, Canada, and Latin America. The appointment is effective July 1. The new structure in the Americas will focus on three areas: strengthening PMI's leadership in Latin America & Canada as the company accelerates toward a smoke-free future; deepening efforts with partners to commercialize reduced risk products in the U.S.; and building a vital launchpad for the company's "beyond nicotine" strategy in the U.S., in coordination with PMI

      6/17/21 7:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    Philip Morris International Inc Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:21:26 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:05:54 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      1/29/24 3:26:29 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Philip Morris International Inc

      SC 13G - Philip Morris International Inc. (0001413329) (Subject)

      2/13/23 3:54:33 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/13/23 2:49:26 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/23 11:30:19 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/7/23 2:10:50 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/11/22 2:48:54 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/10/22 8:32:45 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Philip Morris International Inc. (0001413329) (Subject)

      2/16/21 2:00:14 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    Philip Morris International Inc Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Philip Morris International upgraded by UBS with a new price target

      UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

      4/25/25 8:25:28 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by Argus

      Argus upgraded Philip Morris International from Hold to Buy

      3/14/25 7:44:58 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Morgan Stanley initiated coverage on Philip Morris International with a new price target

      Morgan Stanley initiated coverage of Philip Morris International with a rating of Overweight and set a new price target of $140.00

      1/16/25 7:52:12 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International downgraded by Argus

      Argus downgraded Philip Morris International from Buy to Hold

      3/5/24 7:30:54 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by Societe Generale

      Societe Generale upgraded Philip Morris International from Sell to Hold

      2/13/24 6:43:19 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International downgraded by UBS with a new price target

      UBS downgraded Philip Morris International from Buy to Sell and set a new price target of $86.50 from $105.00 previously

      1/23/24 8:08:22 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Redburn Atlantic initiated coverage on Philip Morris International with a new price target

      Redburn Atlantic initiated coverage of Philip Morris International with a rating of Neutral and set a new price target of $95.00

      11/16/23 7:39:03 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by Citigroup with a new price target

      Citigroup upgraded Philip Morris International from Neutral to Buy and set a new price target of $117.00 from $109.00 previously

      6/20/23 7:42:36 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Stifel resumed coverage on Philip Morris International with a new price target

      Stifel resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $114.00

      4/14/23 7:45:09 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by JP Morgan with a new price target

      JP Morgan upgraded Philip Morris International from Neutral to Overweight and set a new price target of $116.00 from $109.00 previously

      3/30/23 7:41:27 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    Philip Morris International Inc Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres. Smoke-Free Oral Products Dahlgren Lars sold $562,740 worth of shares (3,679 units at $152.96), decreasing direct ownership by 12% to 26,828 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      3/7/25 1:51:03 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • President, Europe Region Andolina Massimo sold $2,730,875 worth of shares (17,500 units at $156.05), decreasing direct ownership by 17% to 86,737 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/25/25 10:49:41 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • President, Europe Region Andolina Massimo covered exercise/tax liability with 823 shares, decreasing direct ownership by 0.78% to 104,237 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/21/25 12:03:21 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Pres. Smoke-Free Oral Products Dahlgren Lars covered exercise/tax liability with 6,925 shares, decreasing direct ownership by 19% to 30,507 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/21/25 12:01:36 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vice President and Controller Dobrowolski Reginaldo covered exercise/tax liability with 247 shares, decreasing direct ownership by 0.99% to 20,594 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/21/25 12:00:03 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Pres. Americas Region Kennedy Stacey covered exercise/tax liability with 4,420 shares, decreasing direct ownership by 8% to 47,765 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/21/25 11:55:15 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Olczak Jacek covered exercise/tax liability with 4,433 shares and sold $5,954,800 worth of shares (40,000 units at $148.87), decreasing direct ownership by 8% to 547,426 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/21/25 11:53:43 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Pr.SmokeFree&ChiefCons.Officer Volpetti Stefano covered exercise/tax liability with 1,502 shares, decreasing direct ownership by 1% to 117,380 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/21/25 11:52:03 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Pr SSEA CIS & MEA Region De Wilde Frederic covered exercise/tax liability with 7,475 shares, decreasing direct ownership by 6% to 121,434 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/21/25 11:50:34 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Babeau Emmanuel covered exercise/tax liability with 13,827 shares and sold $4,465,500 worth of shares (30,000 units at $148.85), decreasing direct ownership by 24% to 139,105 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/21/25 11:48:53 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    Philip Morris International Inc SEC Filings

    See more
    • Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      5/7/25 9:50:34 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      4/30/25 4:29:49 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form FWP filed by Philip Morris International Inc

      FWP - Philip Morris International Inc. (0001413329) (Subject)

      4/30/25 12:57:07 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form FWP filed by Philip Morris International Inc

      FWP - Philip Morris International Inc. (0001413329) (Subject)

      4/28/25 8:33:44 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Philip Morris International Inc

      10-Q - Philip Morris International Inc. (0001413329) (Filer)

      4/24/25 8:26:13 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      4/23/25 7:05:19 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Philip Morris International Inc

      DEFA14A - Philip Morris International Inc. (0001413329) (Filer)

      3/27/25 6:20:40 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Philip Morris International Inc

      DEF 14A - Philip Morris International Inc. (0001413329) (Filer)

      3/27/25 6:16:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      3/25/25 7:13:56 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 25-NSE filed by Philip Morris International Inc

      25-NSE - Philip Morris International Inc. (0001413329) (Subject)

      3/19/25 9:53:20 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    Philip Morris International Inc Financials

    Live finance-specific insights

    See more
    • Philip Morris International Reports First-Quarter 2025 Results and Raises 2025 Full-Year Adjusted Diluted EPS Forecast for Currency Only

      Reported Diluted EPS Grew 24.6% to $1.72 Adjusted Diluted EPS Grew 12.7% to $1.69; and by 17.3% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 first-quarter results.1 "We achieved exceptionally strong performance in the first quarter, with continued volume growth supporting an excellent top-line performance and very strong margin expansion," said Jacek Olczak, Chief Executive Officer. "Our smoke-free business goes from strength to strength, delivering organic growth of over 20% in net revenues and over 33% in gross profit." "We remain confident in our ability to deliver superior results, despite an uncertain and volatile glob

      4/23/25 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Court Approves CCAA Plans to Resolve Tobacco Product-Related Claims and Litigation in Canada

      Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding has approved a plan of compromise and arrangement for RBH (the Plan). The Plan, as approved, will resolve all tobacco product-related claims and litigation in Canada against RBH and its affiliates, including PMI. The court also approved substantially similar plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM). As previously disclosed, RBH's court-appointed mediator and monitor filed a pr

      3/7/25 8:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

      Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on April 10, 2025, to shareholders of record as of March 20, 2025. The ex-dividend date is March 20, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consist

      3/6/25 10:44:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Reports 2024 Fourth-Quarter & Full-Year Results

      Delivers 2024 Reported Diluted EPS of $4.52, or $6.01 before Canada non-cash impairment of $1.49, compared to $5.02 in 2023 and Adjusted Diluted EPS of $6.57, Representing Growth of 9.3%, and 15.6% on Currency-Neutral Basis Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 fourth-quarter and full-year results.1 "2024 was a remarkable year for PMI. We delivered very strong full-year results driven by the continued growth of IQOS and ZYN in addition to a robust combustibles performance," said Jacek Olczak, Chief Executive Officer. "The long-awaited U.S. FDA authorization of all ZYN nicotine pouches currently marketed in the U.S. is further eviden

      2/6/25 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

      Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on January 13, 2025, to shareholders of record as of December 26, 2024. The ex-dividend date is December 26, 2024. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio

      12/12/24 6:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Reports 2024 Third-Quarter & First Nine-Months Results; Raises 2024 Guidance for Reported Diluted EPS to $6.20 - $6.26 and Adjusted Diluted EPS to $6.45 - $6.51

      Third-Quarter Reported Diluted EPS grew 49.2% to $1.97, Adjusted Diluted EPS increased by 14.4% to $1.91 and grew by 18.0% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 third-quarter and first nine-months results.1 "In the third quarter, we delivered exceptionally strong performance, with record quarterly net revenues and earnings per share," said Jacek Olczak, Chief Executive Officer. "This reflects excellent momentum across all regions and categories, with a reacceleration in IQOS adjusted in-market sales growth, strong ZYN volumes, and resilient combustible performance." "As a result of our strong year-to-date delivery, we

      10/22/24 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Court-Appointed Mediator Proposes CCAA Plan to Resolve Tobacco Product-Related Claims and Litigation in Canada

      CCAA Plan Includes PMI's Canadian Affiliate RBH, Deconsolidated Since 2019; If RBH Reconsolidated, Expected to be Incremental to Key PMI Financial Metrics Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantiall

      10/18/24 4:04:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex

      Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE:PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to develop Vectura Fertin Pharma's inhaled therapeutics proprietary pipeline. Vectura will be operated by Phillips Medisize, a Molex company. The sale includes upfront cash consideration of GBP 150 million, subject to customary purchase price adjustments, and potential deferred payments of up to GBP 148 million. The transaction is subject to customary closing conditions, including regulatory approval. "In line with our ambitions, Vectura has enabl

      9/17/24 9:04:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Increases Dividend by 3.8% to Annualized Rate of $5.40 per Share

      Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) has increased the company's regular quarterly dividend by 3.8% to an annualized rate of $5.40 per share. The new quarterly dividend of $1.35 per share, up from $1.30 per share, is payable on October 10, 2024, to shareholders of record as of September 26, 2024. The ex-dividend date is September 26, 2024. For additional dividend information, see www.pmi.com/dividend. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include produc

      9/12/24 7:13:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Reports 2024 Second-Quarter and First-Half Results and Raises Full Year Guidance

      Second-Quarter Reported Diluted EPS grew 52.5% to $1.54 Adjusted Diluted EPS decreased by 0.6% to $1.59; and grew by 10.6% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 second-quarter and first-half results.1 "The excellent momentum of our smoke-free business continued with an outstanding second-quarter and first-half performance," said Jacek Olczak, Chief Executive Officer. "The powerful combination of excellent underlying performance and proactive measures across all categories enabled our business to outperform once again, and we are on track for a strong 2024. As a result, we are raising our full-year guidance, desp

      7/23/24 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care